Crossmark

Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review

Crossref DOI link: https://doi.org/10.1186/s12882-018-0847-z

Published Online: 2018-03-07

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Margiotta, Domenico Paolo Emanuele https://orcid.org/0000-0002-3597-8645
Basta, Fabio

Batani, Veronica

Afeltra, Antonella
More Information

Article History

Received: 24 June 2017

Accepted: 20 February 2018

First Online: 7 March 2018

Consent for publication

: Written informed consent was obtained from the patients for publication of this case reports. All authors give their consent for publication.

: DM and AA received Personal Fees from GlaxoSmithKline for expert testimony.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.